#### **Supplementary Information**

## Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)

Nancy H. L. Leung, Samuel M. S. Cheng, Carolyn A. Cohen, Mario Martín-Sánchez, Niki Y. M. Au, Leo L. H. Luk, Leo C. H. Tsang, Kelvin K. H. Kwan, Sara Chaothai, Lison W. C. Fung, Alan W. L. Cheung, Karl C. K. Chan, John K. C. Li, Yvonne Y. Ng, Prathanporn Kaewpreedee, Janice Z. Jia, Dennis K. M. Ip, Leo L. M. Poon, Gabriel M. Leung, J. S. Malik Peiris, Sophie A. Valkenburg, Benjamin J. Cowling

#### **Table of Contents**

Supplementary Methods	3
Supplementary Results on active surveillance of SARS-CoV-2 infection	4
Supplementary Tables	5
Table S1. Characteristics of 435 trial participants at baseline, whom paired Day 0 and 28 sera were tested by ELISA and surrogate virus neutralization test (sVNT) to evaluate antibodies against ancestral virus after third-dose vaccination.	5
Table S2. Characteristics of randomly selected trial participants at baseline, whom paired Day 0 and 28 sera were tested by plaque reduction neutralization test (PRNT) to evaluate neutralising antibodies against ancestral virus an Omicron BA.1 and BA.2 variants after third-dose vaccination, or whom Day 0, 7 and 28 PBMCs were tested by intracellular cytokine staining (ICS) to evaluate T cell response	d 7
Table S3. Solicited local and systemic reactions anytime during the 7 days after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine	9
Table S4. Reasons for seeking ambulatory care and hospitalization after third-dose vaccination.	11
Table S5. Change in antibody and cell-mediated response after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine	<u>?</u> 12
Table S6. Comparisons of antibody and cell-mediated response between a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine	17
Table S7. Proportions of participants who were responders of cell-mediated response after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine, comparisons between a randomised third dose of CoronaVac or BNT162b2, and comparisons between Day 7 and Day 28 from baseline in each study arm.	? 21
Table S8. List of trial participants with a SARS-CoV-2 infection identified by a RAT or PCR	22
Table S9. (A) Characteristics and (B) immune responses of all vaccinated participants at baseline, stratified by prior two-dose CoronaVac or BNT162b2	24
Supplementary Figures	26
Supplementary Figure S1. A detailed flow chart of participant enrolment for this open-label randomised trial of CoronaVac or BNT162b2 provided as a third vaccine dose in adults who previously received two doses of either vaccine, including reasons for exclusion at each stage	26
Supplementary Figure S2. Boosting of (A) neutralising antibody response and (B) cell-mediated response against	

 

#### **Supplementary Methods**

The flow of participant enrolment, i.e. various stages of eligibility assessment, randomization, vaccination and selection for laboratory testing is described in **Figure S1**. Invitations to participate were extended to community-dwelling adults in Hong Kong through mass promotion efforts including advertisements in newspapers, transportation and social media platforms, mass mailing to residential estates, and invitation to and referrals from members of existing cohorts. Interested individuals completed an online application form or called the study hotline. After completing a standardized screening form to preliminarily screen for eligibility and classification into two groups based on prior receipt of two doses of CoronaVac or BNT162b2, the study was explained in detail and participants expressing willingness to participate were randomized to receive either CoronaVac or BNT162b2 (as the third dose) in a 1:1 ratio and assigned a vaccination appointment accordingly. Shortly before or on arrival at the vaccination appointment, we explained the study again, confirmed eligibility and obtained written informed consent, before administering the study vaccination.

At the vaccination appointment (Day 0), all eligible participants were invited to a designated community vaccination centre, which runs under the government's mass vaccination program and offers COVID-19 vaccination to the general public. Under the supervision of the research team, participants were asked to complete a standardised enrolment questionnaire which included information including demographics, medication use, vaccination history, medical conditions and other health-related information such as smoking status, general functional and health status, and socioeconomic status. We collected a 20ml blood sample from the participants, and then unblinded nurses from the community vaccination centres administered the allocated third-dose vaccine intramuscularly. Participants were asked to return on Day 28 for a blood draw and follow-up assessment. Further follow-up blood draws are scheduled at 182 days and 365 days after vaccination. In a voluntary subset of approximately 35% of participants we collected additional 10ml whole blood samples at day 0, 7 and 28 for analysis of cell-mediated immune responses (CMI). At each encounter for a blood draw we offered a HKD100 (USD13) incentive in the form of a supermarket gift voucher.

After vaccination, participants were provided with vaccination cards and tympanic thermometers, observed for 15-30 minutes for immediate events, and then provided with an ediary and requested to record daily on possible (delayed) adverse events or symptoms for at least 7 days, or until all adverse events disappeared. In the e-diary, participants were first asked whether they have felt unwell at any time during the past 24 hours. In those who felt unwell, they were asked for the presence of a list of provided (solicited) local and systemic adverse events, and any other (unsolicited) symptoms. Unwell participants were also asked to rate whether the reported adverse events have interfered with usual activities (mild - symptoms easily tolerated and did not interfere usual activities; moderate - symptoms interfered but did not prevent usual activities; severe - symptoms were severe and prevented usual activities), on the use of over-the-counter medication for symptom relief, absent from work or school, seeking medical care and hospitalisation. Participants were also asked for any medical care including ambulatory care and hospitalisation after the third-dose vaccination on Day 28, 182 and 365.

From March 2022, all participants were invited to participate in active surveillance to identify COVID-19 and influenza virus infection. Before initiation, consented participants were first asked about whether they had done any rapid antigen test (RAT) or virologic (PCR) test for COVID-19 or influenza before, and if yes whether there was any past COVID-19 or influenza

virus infection defined as a positive test result identified by a RAT or virologic test. Then during active surveillance, all consented participants were provided with complementary COVID-19 RAT kits and asked to test themselves every 4 days ("systematic monitoring"). For each COVID-19 RAT, participants were asked to report and upload a photo of the test result to the study team through an online questionnaire whether the test result was positive or not. Participants were also asked to report any other RAT or virologic (PCR) test results for COVID-19 or influenza, such as those identified via mandatory mass testing requested by the government or voluntary testing for work purposes; or if any symptoms appear. When a positive test result for COVID-19 or influenza was identified, or any symptoms had appeared regardless of the RAT result, participants were asked to complete an online symptom diary daily, to monitor disease severity, medication use and medical attention ("illness episode"). Starting from 4 days after the initiation of the symptom diary, participants were also asked to performed COVID-19 RAT daily until obtaining negative result for two consecutive days. Participants completed the symptom diary daily for at least 7 days, or until all symptoms disappeared with RAT negative for two consecutive days, whichever the later. All COVID-19 RAT positive result identified during systematic monitoring and illness episodes were verified with the uploaded photo whenever available. The active surveillance is continuing with information collected up to May 31 included in the present analyses.

#### Supplementary Results on active surveillance of SARS-CoV-2 infection

378 (84%) participants agreed to participate in active surveillance, had reported information on prior COVID-19 infection, and participated in systematic monitoring through selfadministered COVID-19 RAT at least once during the active surveillance period, including 85/101 (84%) in CC-C, 104/118 (88%) in CC-B, 96/118 (81%) in BB-C and 93/114 (82%) in BB-B arms. After receiving the third dose vaccination and before the start of active surveillance, 42 SARS-CoV-2 infections were identified either by RAT or PCR, including 10, 11, 11 and 10 participants in each arm respectively. During active surveillance from 11 March to 31 May 2022, all participants on average reported RAT result every 4.5 days for a median of 68.5 days (IQR 60, 76). 24 SARS-CoV-2 infections were identified either by systematic RAT or self-reported PCR, including 3, 8, 5 and 8 participants in each arm respectively. Daily symptom diary was triggered by a positive RAT or PCR result, or symptomatic illness, for 53 illness episodes from 52 participants, from which 22 SARS-CoV-2 infections were identified by RAT or PCR, including 3, 9, 3 and 7 participants in each arm respectively. Together, 58 SARS-CoV-2 infections were identified within 4-6 months after third-dose vaccination during which Omicron BA.2 variant was locally circulating, including 13/85 (15.3%) in the CC-C, 16/104 (15.4%) in the CC-B, 16/96 (16.7%) in the BB-C and 13/93 (14.0%) in the BB-B arms, with no significant difference detected between the CC-C and CC-B arms (p = 0.93) nor between the BB-C and BB-B arms (p = 0.56) (Figure 5). A list of all positive COVID-19 results, method of identification and verification can be found in Table S8.

#### **Supplementary Tables**

Table S1. Characteristics of 435 trial participants at baseline, whom paired Day 0 and 28 sera were tested by ELISA and surrogate virus neutralization test (sVNT) to evaluate antibodies against ancestral virus after third-dose vaccination. 435 trial participants who provided paired Day 0 and 28 sera, and whom Day 28 sera were provided within 60 days after third-dose vaccination were included, i.e. the four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a homologous third dose of CoronaVac ("CC-C") or a heterologous third dose of BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a heterologous third dose of CoronaVac ("BB-C") or a homologous third dose of BNT162b2 ("BB-B"). Differences with p-values  $\leq 0.05$  were highlighted in bold. ELISA: enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation test

	All enrolled	Received Core	primary serie onaVac (CC)	s of	Received BNT	primary seri 162b2 (BB)	es of
	and received third dose vaccination	Randomise d to CoronaVac (CC-C)	Randomise d to BNT162b2 (CC-B)	р	Randomise d to CoronaVac (BB-C)	Randomi sed to BNT162b 2 (BB-B)	р
	(n = 451)	(n = 101)	(n = 118)		(n = 118)	(n = 114)	
	n (%)	n (%)	n (%)		n (%)	n (%)	
Female	221 (49)	47 (47)	64 (54)	0.13	51 (43)	59 (52)	0.5
Age (median, IQR)	54 (47-60)	58 (50-64)	52 (43-58)	0.01	56 (47-60)	53 (46- 59)	0.55
Age group (vears)							
<18	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	
18 - 29	22 (5)	5 (5)	5 (4)		5 (4)	7 (6)	
30 - 39	38 (8)	8 (8)	13 (11)		8 (7)	9 (8)	
40 - 49	100 (22)	13 (13)	34 (29)		27 (23)	26 (23)	
50 - 59	173 (38)	36 (36)	45 (38)		47 (40)	45 (39)	
60 - 69	99 (22)	33 (33)	20 (17)		28 (24)	18 (16)	
70 - 79	19 (4)	6 (6)	1 (1)		3 (3)	9 (8)	
≥80	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	
Chinese	443 (98)	100 (99)	116 (98)	0.31	116 (98)	111 (97)	0.79
Obesity							
Underweight	23 (5)	6 (6)	6 (5)	0.97	4 (3)	7 (6)	0.6
Normal	187 (41)	45 (45)	52 (44)		50 (42)	40 (35)	
Overweight	99 (22)	20 (20)	22 (19)		28 (24)	29 (25)	
Obese	142 (31)	30 (30)	38 (32)		36 (31)	38 (33)	
Chronic medical conditions							
Any	104 (23)	21 (21)	21 (18)	>0.99	30 (25)	32 (28)	0.9
Lung disease, including COPD and asthma	3 (1)	2 (2)	0 (0)	0.5	0 (0)	1 (1)	>0.99
Heart disease	5 (1)	2 (2)	1 (1)	>0.99	2 (2)	0 (0)	0.5

Hypertension	45 (10)	9 (9)	10 (8)	>0.99	7 (6)	19 (17)	0.03
Diabetes	13 (3)	6 (6)	2 (2)	0.29	3 (3)	2 (2)	>0.99
Hypercholesterole mia	28 (6)	7 (7)	3 (3)	0.34	9 (8)	9 (8)	>0.99
Kidney disease	1 (0)	0 (0)	0 (0)	>0.99	1 (1)	0 (0)	>0.99
Liver disease	7 (2)	1 (1)	2 (2)	>0.99	2 (2)	2 (2)	>0.99
Cancer	6 (1)	3 (3)	2 (2)	>0.99	0 (0)	1 (1)	>0.99
Days between first and second dose of COVID-19 vaccination (median, IQR)	27 (21-28)	28 (28-29)	28 (28-29)	0.59	21 (21-23)	21 (21- 24)	0.63
Days between second and third (study) dose of COVID-19 vaccination (median, IQR)	232 (200- 247)	236 (211- 245)	236 (214- 247)	0.51	226 (195- 246)	222 (196- 249)	0.98
Smoking							
Ever	20 (4)	8 (8)	7 (6)	>0.99	2 (2)	3 (3)	>0.99
Current	11 (2)	4 (4)	5 (4)	>0.99	1 (1)	1 (1)	>0.99

Table S2. Characteristics of randomly selected trial participants at baseline, whom paired Day 0 and 28 sera were tested by plaque reduction neutralization test (PRNT) to evaluate neutralising antibodies against ancestral virus and Omicron BA.1 and BA.2 variants after third-dose vaccination, or whom Day 0, 7 and 28 PBMCs were tested by intracellular cytokine staining (ICS) to evaluate T cell response against structural peptides of ancestral SARS-CoV-2 virus after third-dose vaccination. Two independent sets of 80 trial participants, 20 selected from each study arm, were randomly selected for PRNT or ICS. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). Differences with p-values  $\leq 0.05$  were highlighted in bold. PRNT: plaque reduction neutralisation test; ICS: intracellular cytokine staining; PBMCs: peripheral blood mononuclear cells.

		Randomly selected for PRNT								Randomly selected for ICS								
	Received to	wo-dose Coro (CC)	naVac		Received ty	wo-dose BNT (BB)	162b2	Received t	wo-dose Corc (CC)	onaVac		Received ty	`162b2					
	Randomise d to CoronaVac (CC-C)	Randomise d to BNT162b2 (CC-B)	р		Randomise d to CoronaVac (BB-C)	Randomise d to BNT162b2 (BB-B)	р		Randomise d to CoronaVac (CC-C)	Randomise d to BNT162b2 (CC-B)	р		Randomise d to CoronaVac (BB-C)	Randomis ed to BNT162b 2 (BB-B)	р			
	(n = 20)	(n = 20)			(n = 20)	(n = 20)			(n = 20)	(n = 20)			(n = 20)	(n = 20)				
	n (%)	n (%)			n (%)	n (%)			n (%)	n (%)			n (%)	n (%)				
Female	8 (40)	11 (55)	0.65		8 (40)	7 (35)	>0.99		9 (45)	8 (40)	>0.99		6 (30)	13 (65)	0.17			
Age (median, IQR)	62 (53-67)	57 (51-60)	0.18		56 (48-61)	52 (39-58)	0.38		58 (51-65)	50 (43-61)	0.07		58 (51-64)	52 (43- 59)	0.08			
Age group (years)	-	-			-	-			-	-			-	-				
<18	0 (0)	0 (0)	0.38		0 (0)	0 (0)	0.24		0 (0)	0 (0)	0.42		0 (0)	0 (0)	0.15			
18 - 29	0 (0)	0 (0)			1 (5)	2 (10)			0 (0)	0 (0)			1 (5)	1 (5)				
30 - 39	1 (5)	1 (5)			1 (5)	3 (15)			0 (0)	3 (15)			0 (0)	2 (10)				
40 - 49	2 (10)	4 (20)			4 (20)	4 (20)			5 (25)	7 (35)			2 (10)	6 (30)				
50 - 59	7 (35)	10 (50)			9 (45)	7 (35)			6 (30)	4 (20)			9 (45)	7 (35)				
60 - 69	7 (35)	5 (25)			5 (25)	1 (5)			7 (35)	5 (25)			8 (40)	3 (15)				
70 - 79	3 (15)	0 (0)			0 (0)	3 (15)			2 (10)	1 (5)			0 (0)	1 (5)				
≥80	0 (0)	0 (0)			0 (0)	0 (0)			0 (0)	0 (0)			0 (0)	0 (0)				

Chinese	19 (95)	20 (100)	>0.99		19 (95)	19 (95)	>0.99		20 (100)	20 (100)	>0.99	20 (100)	20 (100)	>0.99
Obesity	-	-			-	-			-	-		-	-	
Underweight	0 (0)	1 (5)	0.46		0 (0)	1 (5)	>0.99		1 (5)	1 (5)	<0.01	1 (5)	3 (15)	0.71
Normal	10 (50)	6 (30)			9 (45)	8 (40)			14 (70)	4 (20)		8 (40)	7 (35)	
Overweight	4 (20)	4 (20)			7 (35)	7 (35)			2 (10)	2 (10)		5 (25)	3 (15)	
Obese	6 (30)	9 (45)			4 (20)	4 (20)			3 (15)	13 (65)		6 (30)	7 (35)	
Chronic medical conditions	-	-			-	-			-	-		-	-	
Any	2 (10)	4 (20)	0.69		6 (30)	4 (20)	0.75		5 (25)	3 (15)	0.73	6 (30)	5 (25)	>0.99
Lung disease, including COPD and asthma	0 (0)	0 (0)	>0.99		0 (0)	0 (0)	>0.99		2 (10)	0 (0)	0.5	0 (0)	0 (0)	>0.99
Heart disease	0 (0)	0 (0)	>0.99		0 (0)	0 (0)	>0.99		1 (5)	0 (0)	>0.99	1 (5)	0 (0)	>0.99
Hypertension	1 (5)	2 (10)	>0.99		0 (0)	3 (15)	0.25		2 (10)	1 (5)	>0.99	0 (0)	4 (20)	0.12
Diabetes	0 (0)	0 (0)	>0.99		0 (0)	2 (10)	0.5		1 (5)	0 (0)	>0.99	0 (0)	1 (5)	>0.99
Hypercholesterolemi a	1 (5)	1 (5)	>0.99		1 (5)	2 (10)	>0.99		1 (5)	0 (0)	>0.99	2 (10)	2 (10)	>0.99
Kidney disease	0 (0)	0 (0)	>0.99		1 (5)	0 (0)	>0.99		0 (0)	0 (0)	>0.99	1 (5)	0 (0)	>0.99
Liver disease	0 (0)	0 (0)	>0.99		0 (0)	1 (5)	>0.99		0 (0)	0 (0)	>0.99	0 (0)	0 (0)	>0.99
Cancer	1 (5)	0 (0)	>0.99		0 (0)	0 (0)	>0.99		0 (0)	0 (0)	>0.99	0 (0)	0 (0)	>0.99
Days between first and second dose of COVID-19 vaccination (median, IQR)	28 (28-28)	28 (28- 30)	0.04		21 (21-22)	22 (21-24)	0.19		28 (28-28)	29 (28-30)	0.17	21 (21-21)	21 (21- 22)	0.49
Days between second and third (study) dose of COVID-19 vaccination (median, IQR)	238 (228- 244)	236 (215- 247)	0.67		229 (214- 234)	224 (196- 234)	0.67		234 (222- 239)	230 (219- 243)	0.72	232 (222- 241)	230 (194- 250)	0.61
Smoking	-	-			-	_			_	-		-	-	
Ever	1 (5)	0 (0)	>0.99		0 (0)	2 (10)	0.5		0 (0)	0 (0)	>0.99	0 (0)	1 (5)	>0.99
Current	1 (5)	0 (0)	>0.99		0 (0)	0 (0)	>0.99		0 (0)	0 (0)	>0.99	0 (0)	1 (5)	>0.99
				_				_						_

Table S3. Solicited local and systemic reactions anytime during the 7 days after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("CBP"). Differences with p-values ≤ 0.05 were highlighted in bold.

	Received prin	nary series of Co (CC)	oronaVac	Received BN	l primary seri T162b2 (BB)	es of
	Randomised to CoronaVac (CC-C) (n = 91)	Randomised to BNT162b2 (CC-B) (n = 112)	р	Randomise d to CoronaVac (BB-C) (n = 112)	Randomis ed to BNT162b2 (BB-B) (n = 109)	р
	n (%)	n (%)		n (%)	n (%)	
Reported ever feeling unwell	24 (26%)	77 (69%)	<0.001	25 (22%)	67 (61%)	< 0.001
Duration of adverse reactions (Mean, SD)	2.2 (1.8)	3.6 (2.2)	0.0245	2.2 (1.4)	3.0 (1.6)	0.145
Severity score for interfering ususal activities (Mean, SD)	0.08 (0.18)	0.40 (0.44)	<0.001	0.07 (0.17)	0.31 (0.34)	<0.001
Body temperature (Median, IQR)	-	38.2 (38.0,38.4)	-	-	38.4 (38.3,38.6)	-
Solicited local reactions						
Pain	8 (8.8%)	59 (53%)	<0.001	10 (8.9%)	50 (46%)	<0.001
Tenderness	8 (8.8%)	57 (51%)	<0.001	5 (4.5%)	43 (39%)	<0.001
Swelling or hardness	5 (5.5%)	30 (27%)	<0.001	1 (0.9%)	21 (19%)	<0.001
Itchiness	2 (2.2%)	11 (9.8%)	0.027	0 (0%)	9 (8.3%)	0.001
Redness	1 (1.1%)	9 (8.0%)	0.025	0 (0%)	6 (5.5%)	0.013
Solicited systemic reactions						
Headache	5 (5.5%)	32 (29%)	<0.001	7 (6.2%)	28 (26%)	<0.001
Fatigue	4 (4.4%)	32 (29%)	<0.001	4 (3.6%)	24 (22%)	<0.001
Feverish	7 (7.7%)	28 (25%)	0.001	1 (0.9%)	22 (20%)	<0.001
Fever (≥38ºC)	0 (0%)	12 (11%)	0.001	0 (0%)	11 (10%)	<0.001
Chills	4 (4.4%)	18 (16%)	0.008	1 (0.9%)	22 (20%)	<0.001
Drowsiness	5 (5.5%)	24 (21%)	0.001	2 (1.8%)	21 (19%)	<0.001
Myalgia	3 (3.3%)	21 (19%)	<0.001	4 (3.6%)	17 (16%)	0.002
Malaise	2 (2.2%)	13 (12%)	0.011	1 (0.9%)	15 (14%)	<0.001
Pain at the injection arm	2 (2.2%)	10 (8.9%)	0.043	1 (0.9%)	13 (12%)	<0.001
Arthralgia	3 (3.3%)	8 (7.1%)	0.4	2 (1.8%)	13 (12%)	0.003
Loss of appetite	0 (0%)	9 (8.0%)	0.005	2 (1.8%)	10 (9.2%)	0.015
Abdominal distention	0 (0%)	4 (3.6%)	0.13	1 (0.9%)	8 (7.3%)	0.018
Nasal congestion	2 (2.2%)	7 (6.2%)	0.2	0 (0%)	7 (6.4%)	0.006
Chest discomfort	1 (1.1%)	7 (6.2%)	0.077	2 (1.8%)	7 (6.4%)	0.1
Dizziness	4 (4.4%)	12 (11%)	0.1	2 (1.8%)	7 (6.4%)	0.1
Runny nose	3 (3.3%)	13 (12%)	0.029	4 (3.6%)	6 (5.5%)	0.5
Sneezing	2 (2.2%)	7 (6.2%)	0.2	1 (0.9%)	6 (5.5%)	0.063
Phlegm	4 (4.4%)	4 (3.6%)	>0.9	1 (0.9%)	6 (5.5%)	0.063
Cough	3 (3.3%)	12 (11%)	0.045	1 (0.9%)	5 (4.6%)	0.12
Sore throat	3 (3.3%)	10 (8.9%)	0.1	3 (2.7%)	5 (4.6%)	0.5
Nausea	1 (1.1%)	5 (4.5%)	0.2	4 (3.6%)	5 (4.6%)	0.7
Insomnia	2 (2.2%)	8 (7.1%)	0.2	1 (0.9%)	4 (3.7%)	0.2
Diarrhoea	0 (0%)	6 (5.4%)	0.034	3 (2.7%)	3 (2.8%)	>0.9
Body itching	2 (2.2%)	6 (5.4%)	0.3	1 (0.9%)	3 (2.8%)	0.4
Flushing of the face	2 (2.2%)	4 (3.6%)	0.7	0 (0%)	3 (2.8%)	0.12
Chest pain	1 (1.1%)	2 (1.8%)	>0.9	1 (0.9%)	3 (2.8%)	0.4

		1	1	1		1	
Abdominal pain	0 (0%)	1 (0.9%)	>0.9		2 (1.8%)	3 (2.8%)	0.7
Palpitations	0 (0%)	9 (8.0%)	0.005		3 (2.7%)	2 (1.8%)	>0.9
Skin rash	0 (0%)	6 (5.4%)	0.034		0 (0%)	2 (1.8%)	0.2
Constipation	2 (2.2%)	5 (4.5%)	0.5		1 (0.9%)	2 (1.8%)	0.6
Muscle spasms	0 (0%)	0 (0%)	-		0 (0%)	2 (1.8%)	0.2
Ageusia	0 (0%)	1 (0.9%)	>0.9		0 (0%)	1 (0.9%)	0.5
Enlarged lymph nodes	0 (0%)	0 (0%)	-		0 (0%)	1 (0.9%)	0.5
Face swelling	0 (0%)	0 (0%)	-		0 (0%)	1 (0.9%)	0.5
Arm or leg swelling	0 (0%)	0 (0%)	-		2 (1.8%)	1 (0.9%)	>0.9
Vomiting	0 (0%)	0 (0%)	-		2 (1.8%)	1 (0.9%)	>0.9
Facial drooping/ weakness	0 (0%)	0 (0%)	-		0 (0%)	1 (0.9%)	0.5
Nosebleeds	1 (1.1%)	2 (1.8%)	>0.9		0 (0%)	0 (0%)	-
Dyspnea	0 (0%)	2 (1.8%)	0.5		0 (0%)	0 (0%)	-
Confusion	0 (0%)	1 (0.9%)	>0.9		0 (0%)	0 (0%)	-
Anosmia	0 (0%)	0 (0%)	-		0 (0%)	0 (0%)	-
Conjunctivitis	0 (0%)	0 (0%)	-		0 (0%)	0 (0%)	
Loss of consciousness	0 (0%)	0 (0%)	-		0 (0%)	0 (0%)	-
Seizure	0 (0%)	0 (0%)	-		0 (0%)	0 (0%)	-

**Table S4. Reasons for seeking ambulatory care and hospitalization after third-dose vaccination.** The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). Reported discomfort associated with vaccination within the week after third-dose vaccination were highlighted in bold.

	Study arm	Days between third-dose vaccination and seeking ambulatory care	Type of ambulatory care facility	Days between third-dose vaccination and hospitalization	Type of hospitalization facility	Summary
1	BB-B	18	Public Western medical practices	18	Public hospital	NOT related (haemorrhoids)
2	BB-C	3	Private Western medical practices	-	-	NOT related (nausea and dizziness)
3	BB-C	5	Public Western medical practices	-	-	NOT related (diarrhoea)
4	СС-В	1	Other Chinese/ Western medical practices	-	-	Discomfort associated with vaccination within the week after vaccination (muscle pain)
5	CC-B	3	Private Western medical practices	-	-	Discomfort associated with vaccination within the week after vaccination (flu-like symptoms)
6	CC-B	5	Private Chinese medical practices	-	-	Discomfort associated with vaccination within the week after vaccination (flu-like symptoms & fatigue post- vaccination)
7	CC-B	15	Public Western medical practices	-	-	NOT related (anaemia, normal ECG)
8	CC-B	27	Public Western medical practices	-	-	NOT related (flu)
9	CC-C	7	Private Western medical practices	-	-	Discomfort associated with vaccination within the week after vaccination (muscle pain)
10	CC-C	24	Public Western medical practices	-	-	NOT related (flu)

Table S5. Change in antibody and cell-mediated response after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine. (A) Change in antibody response on Day 28 compared to baseline. The mean values for PRNT<sub>50</sub>, PRNT<sub>80</sub> and PRNT<sub>90</sub> titers were considered as geometric mean titer (GMT), and the fold-change in PRNT titers on Day 28 from baseline were considered as geometric mean fold rise (GMFR). Change in (B) IFNy-producing CD4+ and CD8+ T cell responses against structural peptides of ancestral SARS-CoV-2 virus, and (C) their polycytokine production (TNF $\alpha$  and IL-2) and memory phenotype, on Day 7 and Day 28 compared to baseline. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). Differences with p-values  $\leq 0.05$  were highlighted in bold. ELISA: enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation test; PRNT: plaque reduction neutralisation test; ICS: intracellular cytokine staining; OD: optical density; % inhibition: percent inhibition; PRNT<sub>50</sub>, PRNT<sub>80</sub> and PRNT<sub>90</sub>: PRNT titers with endpoints at 50%, 80% and 90% inhibition respectively. Tn: naïve T cells; Tcm: central memory T cells; Tem: effector memory T cells; Teem: terminal effector memory T cells.

		Baseline	Day 28	Baseline vs.	Day 28
	n	Mean	Mean	Fold change	p-value
ELISA OD					
Ancestral virus					
CC-C	100	0.38	1.73	4.5	< 0.001
CC-B	115	0.39	2.43	6.3	<0.001
BB-C	111	1.31	1.8	1.4	<0.001
BB-B	109	1.35	2.35	1.7	<0.001
sVNT % inhibition					
Ancestral virus					
CC-C	100	17	83	5	<0.001
CC-B	115	16	96	6.1	<0.001
BB-C	111	66	87	1.3	<0.001
BB-B	109	70	96	1.4	<0.001
<b>Omicron BA.1 variant</b>					
CC-C	100	6	15	2.5	<0.001
CC-B	115	6	58	10.2	<0.001
BB-C	111	8	19	2.2	<0.001
BB-B	109	7	69	9.6	<0.001
<b>Omicron BA.2 variant</b>					
CC-C	100	5	43	8	<0.001
CC-B	115	6	85	13.6	<0.001
BB-C	111	28	50	1.8	<0.001
BB-B	109	29	90	3.1	<0.001
PRNT50 titer					
Ancestral virus					
CC-C	20	8	109	13.5	<0.001
CC-B	20	10	905	93.7	<0.001
BB-C	20	34	92	2.7	<0.001
BB-B	20	43	816	19	<0.001
Omicron BA.1 variant					
CC-C	20	5	9	1.8	<0.01
СС-В	20	5	75	14.4	<0.001

Table S5A. Changes in antibody response on Day 28 compared to baseline.

BB-C	20	6	8	1.5	<0.01
BB-B	20	6	86	15.5	<0.001
Omicron BA.2 variant					
CC-C	20	6	6	1.1	0.71
CC-B	20	5	80	15.5	<0.001
BB-C	20	5	6	1.2	0.02
BB-B	20	5	67	12.6	<0.001
PRNT <sub>80</sub> titer					
Ancestral virus					
CC-C	20	5	57	10.9	<0.001
CC-B	20	6	520	84.4	<0.001
BB-C	20	17	46	2.7	< 0.001
BB-B	20	21	381	17.8	<0.001
Omicron BA.1 variant					
CC-C	20	5	6	1.3	0.05
CC-B	20	5	39	7.7	<0.001
BB-C	20	5	5	1	>0.99
BB-B	20	5	43	8.6	<0.001
Omicron BA.2 variant					
CC-C	20	5	6	1	>0.99
CC-B	20	5	41	8.3	<0.001
BB-C	20	5	5	1	>0.99
BB-B	20	5	34	6.5	<0.001
PRNT90 titer					
Ancestral virus					
CC-C	20	5	31	6.3	<0.001
CC-B	20	6	331	59.7	<0.001
BB-C	20	10	25	2.5	<0.001
BB-B	20	12	219	18.4	<0.001
Omicron BA.1 variant					
CC-C	20	5	6	1.1	0.15
CC-B	20	5	22	4.4	<0.001
BB-C	20	5	5	1	>0.99
BB-B	20	5	26	5.3	<0.001
Omicron BA.2 variant					
CC-C	20	5	5	1	0.77
CC-B	20	5	25	4.9	<0.001
BB-C	20	5	5	1	>0.99
BB-B	20	5	22	4.4	<0.001

Table S5B. Changes in IFNγ-producing CD4 <sup>+</sup>	and CD8+ T cell responses on Day 7 and Day 28
compared to baseline.	

		Baseline	Day 7	Day 28	Baseline v	aseline vs. Day 7		Baseline vs	. Day 28
	n	Mean	Mean	Mean	Fold change	р		Fold change	р
IFNγ-producing CD4+ cells (per 100,000)									
CC-C	20	877	4248	2241	4.8	<0.001		2.6	0.04
CC-B	20	641	3203	1822	5	<0.01		2.8	<0.01
BB-C	20	3034	2745	2449	0.9	0.9		0.8	0.43
BB-B	20	2196	2087	1383	1	0.85		0.6	0.6
IFNγ-producing CD8+									
cells (per 100,000)									
CC-C	20	208	668	359	3.2	0.13		1.7	0.49
CC-B	20	78	969	98	12.4	<0.01		1.2	0.53
BB-C	20	213	122	218	0.6	0.4		1	0.94
BB-B	20	146	173	164	1.2	0.84		1.1	0.97
IL4-producing CD4+									
cells (per 100,000)									
CC-C	20	124	70	87	0.6	0.38		0.7	0.66
CC-B	20	109	199	33	1.8	0.28		0.3	0.02

BB-C	20	68	64	67	0.9	0.95	1	0.95
BB-B	20	116	177	71	1.5	0.37	0.6	0.38

Table S5C. Changes in poly-cytokine production (TNF $\alpha$  and IL-2) and memory phenotype in IFN $\gamma$ -producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells on Day 7 and Day 28 compared to baseline.

	-	Baseline	Day 7	Day 28	Baseline v	s. Day 7	Baseline vs.	Day 28
	n	Mean	Mean	Mean	Difference	p- value	Difference	p- value
<u>Cytokine polyfunctional</u> <u>quality</u>								
CD4+ T cells								
CC-C	20							
IFN <sub>7</sub> +		45.1%	58.8%	53.3%	13.7%	0.23	8.2%	0.51
IFN $\gamma^+$ TNF $\alpha^+$		11.5%	23.4%	8.1%	11.9%	0.03	-3.5%	0.83
IFNy+ IL2+		2.8%	3.6%	9.3%	0.8%	0.91	6.5%	0.02
IFNγ+ TNFα+ IL2+		10.6%	14.2%	9.3%	3.6%	0.13	-1.3%	0.7
СС-В	20							
IFN <sub>7</sub> +		42.6%	61.7%	61.6%	19.1%	0.14	19.0%	0.07
IFN $\gamma^+$ TNF $\alpha^+$		8.1%	21.4%	9.0%	13.3%	<0.01	1.0%	0.32
IFNy+ IL2+		2.2%	3.1%	3.6%	0.9%	0.73	1.4%	0.25
IFNγ+ TNFα+ IL2+		7.2%	8.8%	5.9%	1.6%	0.43	-1.3%	0.66
BB-C	20							
IFN <sub>7</sub> +		51.2%	50.2%	47.2%	-1.0%	0.72	-4.0%	0.48
IFN $\gamma^+$ TNF $\alpha^+$		15.0%	11.1%	10.6%	-3.9%	0.18	-4.4%	0.18
IFNy+ IL2+		5.4%	10.7%	11.6%	5.4%	0.01	6.3%	0.02
IFNg+ TNFa+ IL2+		18.4%	12.9%	15.6%	-5.4%	0.41	-2.8%	0.76
BB-B	20							
IFN <sub>7</sub> +		48.7%	47.2%	50.9%	-1.4%	0.96	2.2%	0.93
IFN $\gamma^+$ TNF $\alpha^+$		15.0%	14.2%	9.7%	-0.7%	0.74	-5.3%	0.16
IFNy+ IL2+		3.9%	4.3%	6.2%	0.4%	0.75	2.3%	0.14
IFNy+ TNFa+ IL2+		12.5%	9.2%	8.2%	-3.2%	0.78	-4.2%	0.46
CD8+ T cells								
CC-C	20							
IFN <sub>7</sub> +		49.3%	74.4%	51.6%	25.1%	0.2	2.3%	0.68
IFN $\gamma^+$ TNF $\alpha^+$		0.6%	5.5%	3.3%	4.9%	0.02	2.7%	0.02
IFNy+ IL2+		0.0%	0.2%	4.3%	0.2%	>0.99	4.3%	0.04
IFN $\gamma^+$ TNF $\alpha^+$ IL2+		0.1%	0.0%	0.8%	-0.1%	>0.99	0.7%	0.42
СС-В	20							
IFN <sub>7</sub> +		27.5%	71.0%	43.2%	43.5%	0.01	15.7%	0.22
IFN $\gamma^+$ TNF $\alpha^+$		0.9%	4.6%	1.6%	3.7%	0.14	0.7%	0.58
IFNy+ IL2+		1.1%	2.2%	0.2%	1.1%	0.55	-0.9%	0.18
IFNγ+ TNFα+ IL2+		0.5%	2.2%	0.0%	1.7%	0.37	-0.5%	>0.99
BB-C	20							
IFN <sub>7</sub> +		37.1%	34.3%	61.3%	-2.8%	0.81	24.2%	0.06

IPNY TNG"II				1					
IPNy TN2**II	IFNγ+ TNFα+		4.5%	2.6%	2.8%	 -2.0%	0.8	-1.7%	0.48
IPNy TNR" 1.2"IS.5%2.1%2.1%II <t< td=""><td>IFNγ+ IL2+</td><td></td><td>2.8%</td><td>1.1%</td><td>4.5%</td><td> -1.7%</td><td>0.58</td><td>1.7%</td><td>0.48</td></t<>	IFNγ+ IL2+		2.8%	1.1%	4.5%	 -1.7%	0.58	1.7%	0.48
BB-BII<	IFNγ+ TNFα+ IL2+		5.6%	2.1%	1.3%	 -3.5%	0.4	-4.3%	0.31
iPNriPNriii <td>BB-B</td> <td>20</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	BB-B	20							
IPNr TNrc*II6.3%3.9%1.8%I7.2%0.77I.4%0.94IPNr TL2II0.5%0.9%0.9%I0.6%0.56I0.75%0.75%IPNr TNr: IL2II00.9%00.7%I0.7%I0.7%0.	IFN <sub>7</sub> +		30.3%	39.8%	41.2%	9.5%	0.54	11.0%	0.58
IFNy: IL2-II00.5%1.0%0.6%0.6%0.580.5%0.79IFNy: TNFur: IL2-II000.0%1.0%1.0%0.2.7%0.1800.70Memory phenotypeII000000000000Generation of the interval of the inte	IFNγ+ TNFα+		6.3%	3.9%	1.8%	-2.4%	0.77	-4.4%	0.94
IFNy- TNFG-11.2-III <td>IFNy+ IL2+</td> <td></td> <td>0.5%</td> <td>1.0%</td> <td>0.9%</td> <td>0.6%</td> <td>0.58</td> <td>0.5%</td> <td>0.79</td>	IFNy+ IL2+		0.5%	1.0%	0.9%	0.6%	0.58	0.5%	0.79
Image	IFNγ+ TNFα+ IL2+		3.0%	0.2%	1.0%	-2.7%	0.18	-2.0%	0.79
Memory phenotype <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>									
CO4 T cellsIII	<u>Memory phenotype</u>								
C.C.Image: constraint of the symbol image: constraint of the symbol i	CD4+ T cells								
TnII $2.2\%$ $6.9\%$ $4.3\%$ $4.7\%$ $0.03$ $2.1\%$ $0.14$ TeemI $1.9\%$ $4.8\%$ $2.8\%$ $2.9\%$ $0.1$ $0.9\%$ $0.31$ TemI $26.9\%$ $21.2\%$ $19.6\%$ $5.7\%$ $0.48$ $-7.3\%$ $0.32$ TemI $39.1\%$ $67.1\%$ $53.3\%$ $28.0\%$ $<0.01$ $14.2\%$ $0.11$ CC-B20II $0.7\%$ $53.3\%$ $28.0\%$ $<0.01$ $14.2\%$ $0.11$ TnI $6.2\%$ $3.3\%$ $5.2\%$ $-2.9\%$ $0.13$ $-1.0\%$ $0.7$ TeemI $1.4\%$ $0.9\%$ $3.2\%$ $-0.5\%$ $0.72$ $1.8\%$ $0.26$ TemI $1.5\%$ $26.2\%$ $20.6\%$ $10.9\%$ $0.01$ $5.3\%$ $0.12$ TemI $7.2\%$ $2.4\%$ $25.5\%$ $0.02$ $1.40\%$ $0.08$ BB-C20II $0.9\%$ $3.2\%$ $0.5\%$ $0.01$ $1.40\%$ $0.07$ TemI $1.5\%$ $2.0\%$ $3.2\%$ $0.5\%$ $0.6$ $1.8\%$ $0.7$ TemI $25.1\%$ $21.\%$ $19.6\%$ $-3.4\%$ $0.41$ $-5.6\%$ $0.11$ TemI $55.2\%$ $58.9\%$ $57.6\%$ $2.7\%$ $0.66$ $1.8\%$ $0.7$ TemI $25.1\%$ $21.\%$ $2.6\%$ $0.7\%$ $0.64$ $1.4\%$ $0.5\%$ TemI $1.5\%$ $2.6\%$ $58.\%$ $57.\%$ $0.62$ </td <td>СС-С</td> <td>20</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	СС-С	20							
TeemII<	Tn		2.2%	6.9%	4.3%	4.7%	0.03	2.1%	0.14
Tcm         I         2         26.9%         21.2%         19.6%         -5.7%         0.48         -7.3%         0.32           Tem         I         39.1%         67.1%         53.3%         28.0%         <0.01         14.2%         0.11           CC-B         I         I         6.2%         3.3%         5.2%         -2.9%         0.13         -1.0%         0.7           Teem         I         4%         0.9%         3.2%         -0.5%         0.72         1.8%         0.26           Tem         I         4%         0.9%         3.2%         0.05%         0.72         1.8%         0.26           Tem         I         37.1%         64.6%         51.1% <b>27.5%</b> <0.01         14.0%         0.08           BB-C         I         7.2%         2.4%         4.5%         I.4.8%         0.8         I.2.6%         0.49           Tem         I         5.3%         2.0%         3.2%         0.05%         0.6         1.8%         0.07           Tem         I         1.5%         2.0%         5.6%         0.7%         0.64         1.8%         0.07           Tem         I         1.5%	Teem		1.9%	4.8%	2.8%	2.9%	0.1	0.9%	0.31
Tem         I <thi< th="">         I         <thi< th=""> <thi< th=""></thi<></thi<></thi<>	Tcm		26.9%	21.2%	19.6%	-5.7%	0.48	-7.3%	0.32
CC-B         20         Image: Mark Mark Mark Mark Mark Mark Mark Mark	Tem		39.1%	67.1%	53.3%	28.0%	<0.01	14.2%	0.11
InII <th< td=""><td>СС-В</td><td>20</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	СС-В	20							
TeemII<	Tn		6.2%	3.3%	5.2%	 -2.9%	0.13	-1.0%	0.7
TemIIIIS.3%26.2%20.6%I10.9%<0.01S.3%0.12TemII37.1%64.6%51.1%IZ7.5%<0.01	Teem		1.4%	0.9%	3.2%	 -0.5%	0.72	1.8%	0.26
TemII37.1%64.6%51.1%I27.5%<0.01I14.0%0.08BB-C20III <t< td=""><td>Tcm</td><td></td><td>15.3%</td><td>26.2%</td><td>20.6%</td><td> 10.9%</td><td>&lt;0.01</td><td>5.3%</td><td>0.12</td></t<>	Tcm		15.3%	26.2%	20.6%	 10.9%	<0.01	5.3%	0.12
BB-C120111111111Tn1111.5%2.4%4.5%0.5%0.61.8%0.07Teem111.5%2.0%3.2%0.5%0.61.8%0.07Tem1225.1%21.7%19.6%-3.4%0.41-5.6%0.11Tem1256.2%58.9%57.6%2.7%0.561.4%0.56BB-B22011.4%2.6%1.15%0.62-1.3%>0.99Teem223.9%2.4%2.6%1.5%0.62-1.3%>0.99Teem421.1%1.4%2.0%0.3%>0.990.9%0.53Tem4224.7%16.8%18.8%-7.9%0.045.9%0.36Tem4250.4%54.5%51.6%4.1%0.241.2%0.73CD3 T cells42410.3%2.6%0.83-1.2%0.64Teem4250.3%16.5%9.1%10.2%0.112.8%0.5Teem424.1%10.3%2.6%0.83-1.2%0.64Teem425.3%15.2%4.7%0.297.5%0.26Tem426.3%15.2%4.7%0.280.8%0.8Teem425.4	Tem		37.1%	64.6%	51.1%	 27.5%	<0.01	14.0%	0.08
TnII $7.2\%$ $2.4\%$ $4.5\%$ I $-4.8\%$ $0.8$ I $-2.6\%$ $0.49$ TeemII.5% $2.0\%$ $3.2\%$ $0.5\%$ $0.6$ I.8% $0.07$ TcmII $25.1\%$ $21.7\%$ $19.6\%$ $-3.4\%$ $0.41$ $-5.6\%$ $0.11$ TemII $56.2\%$ $58.9\%$ $57.6\%$ $2.7\%$ $0.56$ $1.4\%$ $0.56$ BB-BI20IIIII $14.\%$ $2.7\%$ $0.62$ $1.4\%$ $>0.99$ TeemII $3.9\%$ $2.4\%$ $2.6\%$ I $1.5\%$ $0.62$ $-1.3\%$ $>0.99$ TeemII $1.4\%$ $2.0\%$ I $0.3\%$ $>0.99$ $0.9\%$ $0.53$ TcmII $24.7\%$ $16.8\%$ $18.8\%$ I $-7.9\%$ $0.04$ $-5.9\%$ $0.36$ TemIIIII $1.4\%$ $2.0\%$ IIII $0.24$ $1.2\%$ $0.73$ CD3 T cellsII	BB-C	20							
Teem         I         Second S	Tn		7.2%	2.4%	4.5%	-4.8%	0.8	-2.6%	0.49
Tcm         I         Z         S1.%         Z1.7%         I9.6%         -3.4%         0.41         -5.6%         0.11           Tem         I         S6.2%         S8.9%         S7.6%         Z.7%         0.56         I.4%         0.56           BB-B         Z         Z         Image: Common Section S	Teem		1.5%	2.0%	3.2%	 0.5%	0.6	1.8%	0.07
Tem         I         I         56.2%         58.9%         57.6%         I         2.7%         0.56         I.4%         0.56           BB-B         I <thi< th="">         I         <thi< td=""><td>Tcm</td><td></td><td>25.1%</td><td>21.7%</td><td>19.6%</td><td>-3.4%</td><td>0.41</td><td>-5.6%</td><td>0.11</td></thi<></thi<>	Tcm		25.1%	21.7%	19.6%	-3.4%	0.41	-5.6%	0.11
BB-B12011	Tem		56.2%	58.9%	57.6%	2.7%	0.56	1.4%	0.56
Tn       I       I       3.9%       2.4%       2.6%       I.15%       0.62       I.13%       >0.99         Teem       I       I.1%       I.4%       2.0%       0.3%       >0.99       0.9%       0.53         Tem       I       I.1%       I.4%       2.0%       0.3%       >0.99       0.9%       0.53         Tem       I       I.1%       I.4%       2.0%       I.3%       0.04       -5.9%       0.36         Tem       I       I.1%       I.4%       I.8%       I.1%       0.24       I.2%       0.36         Tem       I       I       S0.4%       S4.5%       S1.6%       I.1%       0.24       I.2%       0.73         CD8' T cells       I       I       I.1.5%       I.1%       I.1% <t< td=""><td>BB-B</td><td>20</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	BB-B	20							
Teem         I	Tn		3.9%	2.4%	2.6%	 -1.5%	0.62	-1.3%	>0.99
Tcm       Image: Ample Amp	Teem		1.1%	1.4%	2.0%	0.3%	>0.99	0.9%	0.53
Tem         I         I         50.4%         54.5%         51.6%         4.1%         0.24         1.2%         0.73           CD8 T cells         I <thi< th=""> <thi< th=""> <thi< th=""></thi<></thi<></thi<>	Tcm		24.7%	16.8%	18.8%	-7.9%	0.04	-5.9%	0.36
CD8* T cells       Image: Selection of the selectio	Tem		50.4%	54.5%	51.6%	4.1%	0.24	1.2%	0.73
CC-C       20       20       14.1%       10.3%       2.6%       0.83       1-1.2%       0.64         Tn       1       1       14.1%       10.3%       2.6%       0.83       -1.2%       0.64         Teem       1       1       6.3%       16.5%       9.1%       10.2%       0.11       2.8%       0.5         Teem       1       1       7.6%       12.3%       15.2%       4.7%       0.29       7.5%       0.26         Tem       1       24.6%       37.1%       25.4%       12.5%       0.28       0.8%       0.8%       0.8%         CC-B       20       1       10.8%       9.9%       12.5%       0.04       6.6%       0.23         Tn       3.4%       10.8%       9.9%       7.4%       0.04       6.6%       0.23         Teem       4       4.5%       9.2%       4.6%       4.6%       0.66       0.1%       0.83         Tem       4       5.9%       19.1%       11.0%       13.3%       0.01       5.1%       0.73         Tem       4       6.2%       40.9%       19.5%       24.7%       0.02       3.3%       >0.99	CD8+ T cells								
Tn       I	СС-С	20							
Teem       Image: Constraint of the constrai	Tn		11.5%	14.1%	10.3%	 2.6%	0.83	-1.2%	0.64
Tcm       7.6%       12.3%       15.2%       4.7%       0.29       7.5%       0.26         Tem       24.6%       37.1%       25.4%       12.5%       0.28       0.8%       0.8         CC-B       20       20       7.5%       10.8%       9.9%       7.4%       0.04       6.6%       0.23         Tem       20       4.5%       9.2%       4.6%       4.6%       0.66       0.1%       0.83         Tcm       20       4.5%       9.2%       4.6%       4.6%       0.66       0.1%       0.83         Tem       20       4.5%       9.2%       4.6%       4.6%       0.66       0.1%       0.83         Tem       20       4.5%       9.2%       4.6%       4.6%       0.66       0.1%       0.83         Tem       20       4.5%       9.2%       4.6%       4.6%       0.66       0.1%       0.73         Tem       20       16.2%       40.9%       19.5%       24.7%       0.02       3.3%       >0.99	Teem		6.3%	16.5%	9.1%	 10.2%	0.11	2.8%	0.5
Tem       24.6%       37.1%       25.4%       12.5%       0.28       0.8%       0.8         CC-B       20       20	Tcm		7.6%	12.3%	15.2%	4.7%	0.29	7.5%	0.26
CC-B       20       20       Image: Constraint of the state of t	Tem		24.6%	37.1%	25.4%	12.5%	0.28	0.8%	0.8
Tn       3.4%       10.8%       9.9%       7.4%       0.04       6.6%       0.23         Teem       4.5%       9.2%       4.6%       4.6%       0.66       0.1%       0.83         Tcm       5.9%       19.1%       11.0%       13.3%       0.01       5.1%       0.73         Tem       16.2%       40.9%       19.5%       24.7%       0.02       3.3%       >0.99	СС-В	20							
Teem         4.5%         9.2%         4.6%         4.6%         0.66         0.1%         0.83           Tcm         5.9%         19.1%         11.0%         13.3%         0.01         5.1%         0.73           Tem         16.2%         40.9%         19.5%         24.7%         0.02         3.3%         >0.99	Tn		3.4%	10.8%	9.9%	7.4%	0.04	6.6%	0.23
Tcm         5.9%         19.1%         11.0%         13.3%         0.01         5.1%         0.73           Tem         16.2%         40.9%         19.5%         24.7%         0.02         3.3%         >0.99	Teem		4.5%	9.2%	4.6%	4.6%	0.66	0.1%	0.83
Tem 16.2% 40.9% 19.5% <b>24.7% 0.02</b> 3.3% >0.99	Tcm		5.9%	19.1%	11.0%	13.3%	0.01	5.1%	0.73
	Tem		16.2%	40.9%	19.5%	 24.7%	0.02	3.3%	>0.99

BB-C	20							
Tn		10.2%	6.2%	14.0%	-4.1%	0.33	3.8%	0.33
Teem		7.2%	3.1%	10.9%	-4.1%	0.48	3.7%	0.72
Tcm		10.7%	6.6%	12.2%	-4.1%	0.27	1.5%	0.75
Tem		21.9%	24.2%	32.9%	2.3%	0.94	11.0%	0.21
BB-B	20							
Tn		9.1%	4.5%	8.1%	-4.6%	0.23	-1.1%	0.62
Teem		3.2%	4.1%	5.5%	0.9%	0.67	2.3%	0.41
Tcm		12.5%	9.7%	9.7%	-2.9%	0.96	-2.9%	0.84
Tem		15.2%	26.8%	21.8%	11.6%	0.2	6.7%	0.37

Table S6. Comparisons of antibody and cell-mediated response between a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine. (A) Comparisons of antibody response on Day 28 between third dose CoronaVac or BNT162b2. The mean values for PRNT<sub>50</sub>, PRNT<sub>80</sub> and PRNT<sub>90</sub> titers were considered as geometric mean titer (GMT), and the fold-difference in PRNT titers between homologous and heterologous third dose were considered as geometric mean fold rise (GMFR). Comparisons of (B) IFNy-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses against structural peptides of ancestral SARS-CoV-2 virus, and (C) their poly-cytokine production (TNFa and IL-2) and memory phenotype, on Day 7 and 28 between third dose CoronaVac or BNT162b2. The mean values of CD4+ or CD8+ T cells were expressed in number of cells per 100,000 cells. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). Differences with p-values ≤ 0.05 were highlighted in bold. ELISA: enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation test; PRNT: plaque reduction neutralisation test; ICS: intracellular cytokine staining; OD: optical density; % inhibition: percent inhibition; PRNT<sub>50</sub>, PRNT<sub>80</sub> and PRNT<sub>90</sub>: PRNT titers with endpoints at 50%, 80% and 90% inhibition respectively; Tn: naïve T cells; Tcm: central memory T cells; Tem: effector memory T cells; Teem: terminal effector memory T cells.

		Baseline				Day 28		
	Third-dose CoronaVac	Third-dose BNT162b2	Fold- differ	р	Third-dose CoronaVac	Third-dose BNT162b2	Fold- differ	р
	Mean	Mean	ence		Mean	Mean	ence	
Prior two-dose Corona	aVac							
ELISA OD								
Ancestral virus	0.38	0.39	1	0.49	1.73	2.43	1.4	<0.001
sVNT % inhibition								
Ancestral virus	17	16	0.9	0.62	83	96	1.2	<0.001
Omicron BA.1 variant	6	6	0.9	0.38	15	58	3.9	<0.001
Omicron BA.2 variant	5	6	1.2	0.15	43	85	2	<0.001
PRNT50 titer								
Ancestral virus	8	10	1.2	0.55	109	905	8.3	<0.001
Omicron BA.1 variant	5	5	1	>0.99	9	75	8	<0.001
Omicron BA.2 variant	6	5	0.9	>0.99	6	80	13	<0.001
PRNT80 titer								
Ancestral virus	5	6	1.2	0.15	57	520	9.2	<0.001
Omicron BA.1 variant	5	5	1	>0.99	6	39	6.1	<0.001
Omicron BA.2 variant	5	5	0.9	0.34	6	41	7.5	<0.001
PRNT90 titer								
Ancestral virus	5	6	1.1	0.08	31	331	10.6	<0.001
Omicron BA.1 variant	5	5	1	>0.99	6	22	4	<0.001

Table S6A. Comparisons of antibody response on Day 0 and 28 between third dose CoronaVac or BNT162b2.

Omicron BA.2 variant	5	5	1	0.34	!	5	25	4.6	<0.001
Prior two-dose BNT16	<u>2b2</u>								
ELISA OD									
Ancestral virus	1.31	1.35	1	0.28	1	.8	2.35	1.3	<0.001
sVNT % inhibition									
Ancestral virus	66	70	1.1	0.17	8	7	96	1.1	<0.001
Omicron BA.1 variant	8	7	0.9	0.23	1	9	69	3.7	<0.001
Omicron BA.2 variant	28	29	1	0.42	5	0	90	1.8	<0.001
PRNT50 titer									
Ancestral virus	34	43	1.3	0.21	9	2	816	8.9	<0.001
Omicron BA.1 variant	6	6	1	>0.99	1	3	86	10.6	<0.001
Omicron BA.2 variant	5	5	1.1	0.34	(	5	67	10.9	<0.001
PRNT80 titer									
Ancestral virus	17	21	1.3	0.21	4	6	381	8.3	<0.001
Omicron BA.1 variant	5	5	1	>0.99		5	43	8.3	<0.001
Omicron BA.2 variant	5	5	1	0.34	!	5	34	6.7	<0.001
PRNT90 titer									
Ancestral virus	10	12	1.2	0.31	2	5	219	8.9	<0.001
Omicron BA.1 variant	5	5	1	>0.99	!	5	26	5.3	<0.001
Omicron BA.2 variant	5	5	1	>0.99		5	22	4.4	<0.001

Table S6B. Comparisons of IFNγ-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses on Day 0, 7 and 28 between third dose CoronaVac or BNT162b2.

		Baseli	ne			Day	7			Day	28	
	Third- dose Corona Vac Mean	Third -dose BNT1 62b2 Mean	Fold- differ ence	р	Third- dose Corona Vac Mean	Third -dose BNT1 62b2 Mean	Fold- differ ence	р	Third -dose Coron aVac Mean	Third -dose BNT1 62b2 Mean	Fold- differ ence	р
Prior two-do	se Corona	Vac (per	100,000)					1				
IFNγ- producing CD4⁺ cells	877	641	0.7	0.58	4248	3203	0.8	0.82	2241	1822	0.8	0.65
IFNγ- producing CD8⁺ cells	208	78	0.4	0.24	668	969	1.5	0.47	359	98	0.3	0.18
IL4- producing CD4+ cells	124	109	0.9	0.87	70	199	2.8	0.26	87	33	0.4	0.36
Prior two-do	se BNT162	2b2 (per	100,000)	<u> </u>								
IFNγ- producing CD4⁺ cells	3034	2196	0.7	0.56	2745	2087	0.8	0.91	2449	1383	0.6	0.21
IFNγ- producing CD8+ cells	213	146	0.7	0.67	122	173	1.4	0.71	218	164	0.8	0.68
IL <del>4-</del> producing CD4+ cells	68	116	1.7	0.37	64	177	2.8	0.24	67	71	1.1	0.81

# Table S6C. Comparisons of poly-cytokine production (TNF $\alpha$ and IL-2) and memory phenotype in IFN $\gamma$ -producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells on Day 0, 7 and 28 between third dose CoronaVac or BNT162b2.

		Base	line			Day	7			Day	28	
	Third- dose Corona Vac Mean	Third- dose BNT16 2b2 Mean	Mean- differe nce	p- value	Third- dose Corona Vac Mean	Third- dose BNT16 2b2 Mean	Mean - differ ence	p- valu e	Third- dose Coron aVac Mean	Third- dose BNT16 2b2 Mean	Mean- differe nce	p- value
Prior two	n-dose Cor	onaVac			Mean	Mean			Mean	Mean		
<u>Cytokine</u>	nolvfuncti	onal avalit	v									
CD4+ T ce	ells	onur quanç	9									
IFNγ <sup>+</sup>	45.1%	42.6%	-2.5%	0.77	58.8%	61.7%	3.0%	0.47	53.3%	61.6%	8.2%	0.24
IFN $\gamma^+$ TNF $\alpha^+$	11.5%	8.1%	-3.5%	0.89	23.4%	21.4%	-2.1%	0.97	8.1%	9.0%	1.0%	0.63
IFNγ+ IL2+	2.8%	2.2%	-0.6%	0.92	3.6%	3.1%	-0.5%	0.97	9.3%	3.6%	-5.7%	0.01
IFNγ+ TNFα+ IL2+	10.6%	7.2%	-3.4%	0.77	14.2%	8.8%	-5.4%	0.06	9.3%	5.9%	-3.5%	0.25
CD8+ T ce	ells											
IFNγ+	49.3%	27.5%	-21.8%	0.09	74.4%	71.0%	-3.4%	0.52	51.6%	43.2%	-8.4%	0.94
IFNγ+ TNFα+	0.6%	0.9%	0.3%	0.65	5.5%	4.6%	-0.9%	0.57	3.3%	1.6%	-1.7%	0.11
IFNγ+ IL2+	0.0%	1.1%	1.1%	0.08	0.2%	2.2%	2.1%	0.07	4.3%	0.2%	-4.0%	0.04
IFNγ+ TNFα+ IL2+	0.1%	0.5%	0.4%	>0.99	0.0%	2.2%	2.2%	0.16	0.8%	0.0%	-0.8%	0.16
Memory	phenotype											
CD4+ T ce	ells											
Tn	2.2%	6.2%	4.0%	0.05	6.9%	3.3%	-3.6%	0.25	4.3%	5.2%	0.8%	0.3
Teem	1.9%	1.4%	-0.5%	0.54	4.8%	0.9%	-3.9%	0.01	2.8%	3.2%	0.4%	0.79
Tcm	26.9%	15.3%	-11.6%	0.25	21.2%	26.2%	5.0%	0.28	19.6%	20.6%	1.0%	0.97
Tem	39.1%	37.1%	-2.0%	0.98	67.1%	64.6%	-2.5%	0.98	53.3%	51.1%	-2.2%	0.73
CD8+ T ce	ells	-		-								
Tn	11.5%	3.4%	-8.1%	0.13	14.1%	10.8%	-3.3%	0.66	10.3%	9.9%	-0.4%	0.31
Teem	6.3%	4.5%	-1.7%	0.92	16.5%	9.2%	-7.3%	0.08	9.1%	4.6%	-4.5%	0.28
Tcm	7.6%	5.9%	-1.8%	>0.99	12.3%	19.1%	6.8%	0.19	15.2%	11.0%	-4.2%	0.18
Tem	24.6%	16.2%	-8.3%	0.53	37.1%	40.9%	3.8%	0.48	25.4%	19.5%	-5.9%	0.36
Prior two	-doso BNI	F162b2										
Cytokine	nolyfuncti	onal avalit	1/									
CD4+T c		unun quunu	y									
IEN <sub>2/</sub> +	51.2%	48 7%	-2.6%	0.8	50.2%	47 2%	-3.0%	>0.99	47 2%	50.9%	3.6%	0.37
$\frac{11 \text{ Ny}}{1 \text{ FNy}^+}$	15.0%	15.0%	-0.1%	0.9	11.1%	14.2%	3.1%	0.27	10.6%	9.7%	-0.9%	0.43
IFNγ <sup>+</sup> IL2 <sup>+</sup>	5.4%	3.9%	-1.5%	0.78	10.7%	4.3%	-6.4%	0.02	11.6%	6.2%	-5.4%	0.04
$\frac{IEP}{IFN\gamma^{+}}$ $TNF\alpha^{+}$ $IL2^{+}$	18.4%	12.5%	-5.9%	0.15	12.9%	9.2%	-3.7%	0.3	15.6%	8.2%	-7.3%	0.08
CD8+ T ce	ells	1	1	1	1	1	1	1	1	1	L	1

IPNL	27 10/	20.20/	( 00/	0 5	24 20/	20.00/		0.00	(1.20/	41 20/	20.10/	0.24
IFINγ+	37.1%	30.3%	-6.8%	0.5	34.3%	39.8%	5.5%	0.66	61.3%	41.2%	-20.1%	0.34
IFNγ+ TNFα+	4.5%	6.3%	1.7%	0.89	2.6%	3.9%	1.3%	0.73	2.8%	1.8%	-1.0%	0.52
IFNγ+ IL2+	2.8%	0.5%	-2.3%	0.53	1.1%	1.0%	0.0%	>0.99	4.5%	0.9%	-3.6%	0.06
IFNγ+ TNFα+ IL2+	5.6%	3.0%	-2.6%	0.43	2.1%	0.2%	-1.8%	0.53	1.3%	1.0%	-0.3%	>0.99
Memory	phenotype											
CD4+ T ce	ells											
Tn	7.2%	3.9%	-3.3%	0.41	2.4%	2.4%	0.0%	0.98	4.5%	2.6%	-1.9%	0.24
Teem	1.5%	1.1%	-0.4%	0.82	2.0%	1.4%	-0.6%	0.58	3.2%	2.0%	-1.2%	0.12
Tcm	25.1%	24.7%	-0.5%	0.94	21.7%	16.8%	-5.0%	0.36	19.6%	18.8%	-0.7%	0.8
Tem	56.2%	50.4%	-5.8%	0.68	58.9%	54.5%	-4.4%	0.94	57.6%	51.6%	-6.1%	0.61
CD8+ T ce	ells											
Tn	10.2%	9.1%	-1.1%	0.94	6.2%	4.5%	-1.7%	>0.99	14.0%	8.1%	-6.0%	0.25
Teem	7.2%	3.2%	-4.0%	0.57	3.1%	4.1%	1.0%	0.52	10.9%	5.5%	-5.4%	0.5
Tcm	10.7%	12.5%	1.9%	0.86	6.6%	9.7%	3.1%	0.6	12.2%	9.7%	-2.5%	0.55
Tem	21.9%	15.2%	-6.7%	0.54	24.2%	26.8%	2.6%	0.81	32.9%	21.8%	-11.1%	0.21

Table S7. Proportions of participants who were responders of cell-mediated response after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine, comparisons between a randomised third dose of CoronaVac or BNT162b2, and comparisons between Day 7 and Day 28 from baseline in each study arm. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). Differences with p-values ≤ 0.05 were highlighted in bold.

		Baseline			Day 7			Day 28		Baseline	vs. Day 7	Baseline	vs. Day 28
	Third- dose Corona Vac	Third- dose BNT16 2b2	р	Third- dose CoronaV ac	Third- dose BNT16 2b2	р	Third- dose Corona Vac	Third- dose BNT16 2b2	р	Third- dose CoronaVac	Third- dose BNT162b2	Third- dose CoronaVac	Third- dose BNT162b2
	n (%)	n (%)		n (%)	n (%)		n (%)	n (%)		р	р	р	р
Prior two-dose Coro	<u>naVac</u>												
IFNγ-producing CD4+ cells	14 (70)	12 (60)	0.74	20 (100)	19 (95)	>0.99	16 (80)	16 (80)	>0.99	0.03	0.02	0.72	0.3
IFNγ-producing CD8+ cells	10 (50)	6 (30)	0.33	16 (80)	16 (80)	>0.99	12 (60)	9 (45)	0.53	0.1	<0.01	0.75	0.51
IL4-producing CD4+ cells	13 (65)	15 (75)	0.73	12 (60)	14 (70)	0.74	13 (65)	15 (75)	0.73	>0.99	>0.99	>0.99	>0.99
Prior two-dose BNT1	<u>62b2</u>												
IFNγ-producing CD4+ cells	18 (90)	16 (80)	0.66	17 (85)	15 (75)	0.69	17 (85)	15 (75)	0.69	>0.99	>0.99	>0.99	>0.99
IFNγ-producing CD8+ cells	10 (50)	8 (40)	0.75	8 (40)	9 (45)	>0.99	14 (70)	9 (45)	0.2	0.75	>0.99	0.33	>0.99
IL4-producing CD4+ cells	12 (60)	13 (65)	>0.99	12 (60)	15 (75)	0.5	12 (60)	13 (65)	>0.99	>0.99	0.73	>0.99	>0.99

**Table S8. List of trial participants with a SARS-CoV-2 infection identified by a RAT or PCR.** Altogether, (A) a total of 58 COVID-19 infection were identified either by RAT or PCR after third-dose vaccination until 31 May 2022 by various means, including (B) self-reported positive RAT or PCR result before the start of active surveillance, (C) during active surveillance, systematic monitoring for SARS-CoV-2 infection with self-administered RAT every 4 days, and (D) during active surveillance, upon a reported illness episode self-administered RAT daily starting from 4 days after the initiation of symptom diary. All COVID-19 RAT positive result identified during systematic monitoring and illness episodes were verified with the photo of the test kit whenever available. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-B"). RAT: rapid antigen test; PCR: polymerase chain reaction. 1: Yes; 0: No; -: Unknown.

				A: Sum SARS- infe iden	mary of CoV-2 ction tified	B: Re initia su	ported b ition of a irveillan	efore ctive ce	C: Rep syste	orted du matic mo	ring activ nitoring f infection	e surveil for SARS-	lance - CoV-2	D: Rep Daily	orted du symptoi	ring activ m diary u episode	ve survei Ipon an il	llance - llness
	Study arm	Date of third-dose vaccination (Month/ Year)	Date of COVID-19 infection (Month/ Year)	Positiv e verifie d with picture of RAT	Sympto matic illness	Positi ve by RAT or PCR	Positi ve by RAT	Positi ve by PCR	Positiv e by RAT or PCR	Positiv e by RAT	RAT result verifie d	Positiv e by PCR	Sympt omatic illness	Positi ve by RAT or PCR	Positi ve by RAT	RAT result verifie d	Positi ve by PCR	Sympt omatic illness
1	CC-C	11/21	2/22	0	0	1	1	1	0	0	-	-	-	-	-	-	-	-
2	CC-C	11/21	3/22	1	1	1	1	1	1	1	1	-	1	1	0	-	1	1
3	CC-B	11/21	3/22	1	1	0	0	0	0	0	1	0	1	1	1	1	-	1
4	CC-B	11/21	3/22	1	1	-	-	-	0	0	1	-	1	1	1	1	-	1
5	CC-B	12/21	3/22	1	1	1	1	-	1	1	1	-	1	1	1	0	1	1
6	CC-B	12/21	3/22	1	1	1	1	-	1	1	0	-	1	1	1	1	-	1
7	CC-B	12/21	3/22	1	0	1	1	0	1	0	1	1	0	1	0	-	1	0
8	BB-C	12/21	3/22	1	0	-	-	-	1	1	1	-	0	0	0	-	0	0
9	CC-B	12/21	3/22	0	0	1	1	1	0	0	-	0	-	-	-	-	-	-
10	CC-B	12/21	2/22	0	0	1	1	1	0	0	-	-	-	-	-	-	-	-
11	CC-B	12/21	3/22	1	1	-	0	-	1	1	1	0	1	1	1	1	1	1
12	CC-C	12/21	2/22	0	0	1	1	1	0	0	-	-	-	-	-	-	-	-
13	CC-C	12/21	3/22	0	1	-	0	-	1	1	0	-	1	1	1	0	-	1
14	BB-C	12/21	2/22	0	0	1	1	1	0	0	-	-	-	-	-	-	-	-
15	CC-C	12/21	2/22	1	1	1	1	1	0	0	1	0	0	0	0	-	0	1
16	CC-C	12/21	2/22	0	0	1	1	-	0	0	-	-	-	-	-	-	-	-
17	CC-C	12/21	3/22	0	0	1	1	1	0	0	-	-	-	-	-	-	-	-
18	CC-C	12/21	2/22	0	0	1	1	1	0	0	-	-	-	-	-	-	-	-
19	CC-C	12/21	2/22	0	0	1	1	1	0	0	-	-	-	-	-	-	-	-
20	CC-B	12/21	2/22	0	0	1	1	0	0	0	-	0	-	-	-	-	-	-

21	CC-B	12/21	3/22	1	1	1	1	1	0	0	1	0	1	1	-	-	1	1
22	CC-B	12/21	4/22	1	1	-	0	-	1	1	1	-	0	1	1	1	-	1
23	CC-B	12/21	3/22	1	1	1	1	1	1	1	1	-	1	1	1	1	-	1
24	BB-C	12/21	3/22	0	0	1	1	-	0	0	-	-	-	-	-	-	-	-
25	BB-C	12/21	3/22	1	1	0	0	0	1	1	1	-	0	1	1	1	-	1
26	CC-C	12/21	3/22	1	1	0	0	0	0	0	1	0	1	1	-	1	-	1
27	CC-B	12/21	3/22	1	1	-	0	-	1	1	1	-	1	0	0	-	-	1
28	CC-C	1/22	3/22	0	0	1	1	-	0	-	-	-	-	-	-	-	-	-
29	BB-C	1/22	4/22	1	1	0	0	0	1	1	1	1	1	1	1	1	-	1
30	BB-B	1/22	3/22	0	0	1	1	-	0	0	-	0	-	-	-	-	-	-
31	BB-B	1/22	3/22	0	0	1	1	0	0	0	-	0	-	-	-	-	-	-
32	BB-B	1/22	3/22	1	1	0	0	0	1	1	1	1	1	1	1	1	-	1
33	BB-B	1/22	3/22	1	1	0	0	0	0	0	1	-	1	1	1	1	-	1
34	BB-B	1/22	3/22	0	1	1	1	1	1	1	0	1	1	1	0	-	1	1
35	BB-B	1/22	3/22	0	1	1	1	1	1	1	0	1	1	1	0	-	1	1
36	CC-B	1/22	3/22	0	0	1	1	0	0	0	-	-	-	-	-	-	-	-
37	BB-C	1/22	2/22	0	0	1	0	1	0	0	-	-	-	-	-	-	-	-
38	BB-C	1/22	3/22	1	1	1	1	0	1	1	1	-	1	0	0	-	-	1
39	CC-C	1/22	3/22	0	0	1	1	0	0	0	-	-	-	-	-	-	-	-
40	CC-C	1/22	3/22	1	1	0	0	0	1	1	1	-	1	0	0	-	-	1
41	BB-C	1/22	2/22	0	0	1	0	1	0	0	-	0	-	-	-	-	-	-
42	CC-B	1/22	3/22	1	1	1	-	1	1	1	1	-	0	0	0	-	0	1
43	BB-B	1/22	3/22	1	1	1	1	-	1	1	1	1	1	-	-	-	-	1
44	BB-B	1/22	3/22	0	0	1	1	1	0	0	-	0	-	-	-	-	-	-
45	BB-B	1/22	3/22	1	1	1	1	0	1	1	1	-	1	0	0	-	-	1
46	BB-C	1/22	4/22	1	1	0	0	0	1	1	1	1	1	0	0	-	0	1
47	BB-C	1/22	2/22	0	0	1	1	-	0	0	-	-	-	-	-	-	-	-
48	BB-C	1/22	3/22	1	1	1	1	-	0	0	1	0	1	0	0	-	0	1
49	BB-B	1/22	3/22	1	1	1	1	0	1	1	1	0	1	1	0	-	1	1
50	BB-B	1/22	2/22	0	0	1	1	-	0	0	-	-	-	-	-	-	-	-
51	BB-B	1/22	5/22	1	1	-	-	-	1	1	1	1	1	1	0	-	1	1
52	BB-C	1/22	2/22	0	0	1	1	1	0	0	-	-	-	-	-	-	-	-
53	BB-C	1/22	2/22	0	0	1	1	1	0	0	-	0	-	-	-	-	-	-
54	BB-C	1/22	3/22	1	1	1	1	1	0	0	1	-	0	-	-	-	-	1
55	BB-C	1/22	3/22	1	1	-	0	-	0	0	1	-	0	1	0	-	1	1
56	BB-C	1/22	2/22	0	0	1	1	1	0	0	-	0	-	-	-	-	-	-
57	CC-B	1/22	3/22	0	0	1	1	1	0	0	-	0	-	-	-	-	-	-
58	BB-B	1/22	3/22	1	1	1	1	0	1	1	1	-	1	1	0	- 1	1	1

Table S9. (A) Participant characteristics, as well as (B) antibody and cell-mediated responses of all vaccinated participants at baseline, stratified by prior two-dose CoronaVac or BNT162b2. We enrolled 219 adults who previously received two doses of CoronaVac and 232 adults who previously received two doses of BNT162b2, and randomly assigned participants to receive either vaccine as a third dose in each group. Differences with p-values  $\leq 0.05$  were highlighted in bold. ELISA: enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation test; PRNT: plaque reduction neutralisation test; ICS: intracellular cytokine staining; OD: optical density; % inhibition: percent inhibition; PRNT<sub>50</sub>, PRNT<sub>80</sub> and PRNT<sub>90</sub>: PRNT titers with endpoints at 50%, 80% and 90% inhibition respectively.

<b>^</b>	Received primary	Received primary Received primary			
	series of CoronaVac series of BNT162b2				
	(CC)	(BB)	р		
	(n = 219)	(n = 232)	•		
	n (%)	n (%)			
Female	111 (51)	110 (47)	>0.99		
Age (median, IQR)	55 (47-61)	54 (46-60)	0.99		
Age group (years)					
<18	0 (0)	0 (0)			
18 - 29	10 (5)	12 (5)			
30 - 39	21 (10)	17 (7)			
40 - 49	47 (21)	53 (23)			
50 - 59	81 (37)	92 (40)			
60 - 69	53 (24)	46 (20)			
70 - 79	7 (3)	12 (5)			
≥80	0 (0)	0 (0)			
Chinese	216 (99)	227 (98)	0.63		
Obesity					
Underweight	12 (5)	11 (5)	0.49		
Normal	97 (44)	90 (39)			
Overweight	42 (19)	57 (25)			
Obese	68 (31)	74 (32)			
Chronic medical conditions					
Any	42 (19)	62 (27)	0.06		
Lung disease, including COPD and asthma	2 (1)	1 (0)	>0.99		
Heart disease	3 (1)	2 (1)	>0.99		
Hypertension	19 (9)	26 (11)	0.37		
Diabetes	8 (4)	5 (2)	0.58		
Hypercholesterolemia	10 (5)	18 (8)	0.18		
Kidney disease	0 (0)	1 (0)	>0.99		
Liver disease	3 (1)	4 (2)	>0.99		
Cancer	5 (2)	1 (0)	0.22		
Days between first and second dose of COVID-19	28 (28-20)	21 (21-22)	<0.01		
vaccination (median, IQR)	20 (20-29)	21 (21-23)			
Days between second and third (study) dose of	236 (213-247)	224 (195-246)	0.02		
COVID-19 vaccination (median, IQR)	200 (210-277)	227 (175-270)	0.02		
Smoking					
Ever	15 (7)	5 (2)	0.04		
Current	9 (4)	2 (1)	0.07		

#### Table S9A. Participant characteristics at baseline.

	Received primary series of CoronaVac (CC)	Received primary series of BNT162b2 (BB)	Fold- difference	р
	(n = 219)	(n = 232)		
	Mean	Mean		
Antibody response				
ELISA OD				
Ancestral virus	0.38	1.33	3.5	<0.01
sVNT % inhibition				
Ancestral virus	16	68	4.2	<0.01
Omicron BA.1 variant	6	8	1.3	<0.01
Omicron BA.2 variant	6	29	4.9	<0.01
PRNT50 titer				
Ancestral virus	9	38	4.3	<0.01
Omicron BA.1 variant	5	6	1.1	0.14
Omicron BA.2 variant	5	5	1.0	0.57
PRNT80 titer				
Ancestral virus	6	19	3.4	<0.01
Omicron BA.1 variant	5	5	1.0	
Omicron BA.2 variant	5	5	1.0	>0.99
PRNT90 titer				
Ancestral virus	5	11	2.1	<0.01
Omicron BA.1 variant	5	5	1.0	
Omicron BA.2 variant	5	5	1.0	0.33
Cell-mediated response				
IFNγ-producing CD4+ responder (n, %)	26 (65)	34 (85)	-	0.07
IFNγ-producing CD8+ responder (n, %)	16 (40)	18 (45)	-	0.82
IL4-producing CD4 <sup>+</sup> cells responder (n, %)	28 (70)	25 (63)	-	0.64
IFNγ-producing CD4+ cells (per 100,000)	750	2581	3.4	<0.01
IFNγ-producing CD8+ cells (per 100,000)	128	176	1.4	0.58
IL4-producing CD4+ cells (per 100,000)	116	89	0.8	0.73

### Table S9B. Antibody and cell-mediated response at baseline.

#### **Supplementary Figures**

Figure S1. A detailed flow chart of participant enrolment for this open-label randomised trial of CoronaVac or BNT162b2 provided as a third vaccine dose in adults who previously received two doses of either vaccine, including reasons for exclusion at each stage. (A) From eligibility assessment for enrolment to randomisation of study intervention. (B) From randomisation to administration of study intervention. (C) From administration of study intervention to selection of paired Day 0 and Day 28 blood samples for laboratory testing.









Figure S2. Boosting of (A) neutralising antibody response and (B) cell-mediated response against ancestral SARS-CoV-2 virus, Omicron BA.1 and BA.2 variants at Day 7 and/or Day 28 after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine, measured by live virus plaque reduction neutralization test (PRNT) or intracellular cytokine staining (ICS) respectively. PRNT titers were evaluated with endpoint at 50% inhibition (PRNT50). The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). The symbol X and the numbers above each panel indicate the fold-change compared to baseline (Day 0). D28/D0: comparison between Day 28 against Day 0; D7/D0: comparison between Day 7 against Day 0.



Figure S3. Serum antibodies against ancestral SARS-CoV-2 virus at baseline and 28 days after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine, measured by (A) ELISA, (B) surrogate virus neutralization test (sVNT) or (C) live virus plaque reduction neutralization test (PRNT). PRNT titers were evaluated with endpoint at 50% inhibition (PRNT50). The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 ("CC-B"), and third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). The symbol X and the numbers above each panel indicate the mean level. p-values  $\leq 0.05$  \*,  $\leq 0.01$  \*\*,  $\leq 0.001$  \*\*\*



Figure S4. Serum neutralising antibodies against (A-C) ancestral SARS-CoV-2 virus, (D-F) Omicron BA.1 and (G-I) Omicron BA.2 variants at baseline and 28 days after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine, measured by live virus plaque reduction neutralization test (PRNT) with endpoints at 50% (PRNT50), 80% (PRNT80) and 90% (PRNT90) respectively. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-C") or BNT162b2 ("BB-B"). The symbol X and the numbers above each panel indicate the mean level.



Figure S5. IL-4 producing CD4+ T cells against structural peptides of ancestral SARS-CoV-2 virus at baseline, and 7 and 28 days after a randomised third dose of CoronaVac or BNT162b2 vaccine in adults who previously received two doses of either vaccine. Data was available from a random subset of 20 participants selected from each study arm. The four study arms included participants who previously received two-dose CoronaVac and were randomised to receive a third dose of CoronaVac ("CC-C") or BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 ("CC-B"), and participants who previously received two-dose BNT162b2 and were randomised to receive a third dose of CoronaVac ("BB-B"). The dotted lines represent the lower limits of detection based on DMSO controls and participants with values above these thresholds are considered as responders: 0.000039% for CD4+ IL4+ T cells. The numbers above each panel indicate the mean level, while the percentages indicate the proportion of responder. p-values  $\leq 0.05^*$ ,  $\leq 0.01^{**}$ ,  $\leq 0.001^{***}$ 

